Did you know 8.7% of #psoriasis patients also have psoriatic arthritis (PsA)? Early detection is key! Dermatologists can spot PsA before joint symptoms begin using tools like the EARP-PT questionnaire, which helps flag PsA risks with ease.
🌐Read more: https://t.co/hNloI7dYpg
Check out the latest update of @eular_org recommendations for #systemic#sclerosis treatment
▶️ 22 recommendations covering 8 clinical domains
▶️ new recommendations on treatments for skin fibrosis and lung disease
▶️ first- & second-line interventions
🔗 https://t.co/QopiRZnX7Z
Our latest study is out, led by Dr Qianru Zhang- a comprehensive literature review and meta-analysis of all DMARDs and future risk of RA-ILD.
40 studies, 486K RA patients, 4K incident ILD cases
✔️NO increased risk for any DMARD
https://t.co/oO9Z3Hp1DR
On October 22nd at 2:00 PM, Christiane Fiorin from Elsevier will lead a session for current and aspiring authors on the article publication process at #NOVAMedicalSchool. Topics include manuscript prep, peer review, and open access.
Sign up here: https://t.co/4uqTy29M6D
Mexer o corpo para prevenir quedas! Atividade ao ar livre com a comunidade sénior de Arroios. Uma iniciativa da Nova Medical School.
@nova_medschool https://t.co/Z315q7z6gz
🎓 Take the next step in your academic and professional career.
➡ Learn more about the Master's Degree in Epidemiology, Biostatistics and Health Research (EpiBIS) and sign up here: https://t.co/vLGncs8uT9
Happy to announce @nova_medschool 1st Edition of the ADVANCED TRAINING IN NEW IN VITRO MODELS!
Check details about the training here 👇
https://t.co/ivwBqMi8LU
A limited number of participants!
📣Don’t miss it!
A NOVA Medical School launched the #CHAINBiobank, a bank of human biological samples, available to the entire national and international scientific community.
Experts gathered to discuss importance of #Biobanks in #health#research and #innovation.
📽️ https://t.co/51AzJv2bXY
@romaovc@SPReumatologia@ern_reconnet@TaniaLSantiago@jecfonseca Great talks! All the talks reinforced the need to learn more about individual risk (risk stratification). Also the need to have better treatment options (in terms of efficacy and safety) for early phases of rheumatic inflammatory diseases.